Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Research And Development Expense of $475.27 million for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +51.2% in Research And Development Expense from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $12.84 million | Q2 2020: $13.24 million | Q3 2020: $16.54 million | Q1 2021: $24.11 million | Q2 2021: $29.62 million | Q3 2021: $33.25 million | Q1 2022: $32.44 million | Q2 2022: $38.44 million | Q3 2022: $40.84 million | Q1 2023: $46.68 million | Q2 2023: $55.06 million | Q3 2023: $70.01 million | Q1 2024: $67.56 million | Q2 2024: $73.93 million | Q3 2024: $74.60 million | Q1 2025: $129.63 million | Q2 2025: $128.64 million | Q3 2025: $121.06 million.
- Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 937.5%.
- Historical annual values: Fiscal year 2025: $475.27 million | Fiscal year 2024: $314.42 million | Fiscal year 2023: $241.23 million | Fiscal year 2022: $155.70 million | Fiscal year 2021: $135.27 million | Fiscal year 2020: $63.32 million | Fiscal year 2019: $45.81 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: